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266 Abstracts July 2014were analyzed by binary logistic regression for each health-care system, after
adjustment for age, sex, year, and Charlston comorbidity index. The study
included 11,799 patients with rAAA in England and 23,838 patients with
rAAA in the USA. In-hospital mortality was lower in the USA than in En-
gland (53.05% [95% CI, 51.26-54.85] vs 65.9%; P < .0001). Intervention
(open or endovascular repair) was offered to a greater proportion of cases in
the USA than in England (19,174 [80.43%] vs 6897 [58.45%]; P < .0001).
Endovascular repair was more common in the USA than in England (4003
[20.88%] vs 589 [8.54%]; P < .0001). Postintervention mortality was
similar in both countries (41.77% for England and 41.65% for USA). Obser-
vations were no different in age-matched and sex-matched comparisons. In
both countries reduced mortality was associated with increased use of endo-
vascular repair, increased hospital caseload (volume) for rAAA, high hospital
bed capacity, hospitals with teaching status, and admission on a weekday.
Comment: The data demonstrate that in-hospital mortality for pa-
tients with rAAA is lower in the USA than England with the difference
mainly attributed to the fact that in the U.S. patients were less likely to
be managed by non-corrective measures and aneurysm repair was offered
for a greater proportion of patients with rAAA. Even though endovascular
repair was more common in the USA, overall operative mortality was similar
in the two countries. In both countries, outcomes are better in hospitals
with larger volumes, teaching hospitals, and when patients are admitted dur-
ing regular working hours. It is unclear if these are independent correlates or
whether hospital capacity, teaching status and admission on a week day as
well as rAAA caseload are all basically interrelated surrogate markers for
the immediacy with which patients with rAAA have access to a full range
of technology and care by a specialized multi-disciplinary team. However,
the authors conclude that “service conﬁguration should focus on insuring
that patients with rAAA are treated in a teaching hospital with a high aortic
workload, offering both conventional and endovascular repair”.
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Conclusions: Six months following renal-artery denervation in pa-
tients with resistant hypertension there is no signiﬁcant reduction of systolic
blood pressure.
Summary: Resistant hypertension is deﬁned as a systolic blood pres-
sure of $140 mm Hg despite adherence to at least three maximally toler-
ated doses of antihypertensive medications from complimentary classes,
including a diuretic at an appropriate dose (Smith SM et al, J Hypertens
2013; 32:635-43). Approximately 10% of patients with hypertension have
resistant hypertension. Cross-talk between the kidneys and the brain medi-
ated by the sympathetic nervous system appears to play an important role in
resistant hypertension (Bakris G et al, J Am Coll Cardiol 2013 November
25 [Epub ahead of print]). Recently, catheter-based radiofrequency dener-
vation of the renal arteries has emerged as a potential treatment for resistant
hypertension and is already in clinical use in more than 80 countries
including parts of Europe, South America, Australia, and Canada. Initial
nonrandomized studies and randomized, unblinded trials have shown sig-
niﬁcant reductions in blood pressure, as measured at ofﬁce visits, after renal
denervation (Krum H et al, Lancet 2009; 373:1275-81). However, initial
studies have included small sample sizes, and limited assessment of ambula-
tory blood pressure, and had not utilized blinding, or a sham procedures.
These drawbacks have limited broad application of the ﬁndings as poten-
tially unreliable. In this trial the authors performed a prospective, single-
blind, randomized, sham-controlled trial, to try and overcome many of
the previous methodology limitations of previous smaller studies. Patients
with severe resistant hypertension were randomly assigned in a 2 to 1 ratio
to undergo renal-denervation or a sham procedure. Prior to randomization
patients received a stable antihypertensive regimen involving maximally
tolerated doses of at least three drugs, including a diuretic. The primary ef-
ﬁcacy end point of the trial was the change in ofﬁce systolic blood pressure
at 6 months; a secondary efﬁcacy end point was the change in mean 24-hour
ambulatory systolic blood pressure. The primary safety end point was a com-
posite of death, end-stage renal disease, embolic events resulting in end-or-
gan damage, renovascular complications, or hypertensive crisis at 1 month
or new renal-artery stenosis of more than 70% at 6 months. There were a
total of 535 patients who underwent randomization. The mean (6SD)
change in systolic blood pressure at 6 months was 14.13 6 23.93 mm
Hg in the denervation group as compared with 11.74 6 25.94 mm Hgin the sham-procedure group (P < .001 for both comparisons of the change
from baseline), for a difference of 2.39 mm Hg (95% CI, 6.89 to 2.12; P
¼ .26 for superiority with a margin of 5 mm Hg). The change in 24-hour
ambulatory systolic blood pressure was 6.75 6 15.11 mm Hg in the
denervation group and 4.79 6 17.25 mm Hg in the sham-procedure
group, for a difference of 1.96 mm Hg (95% CI, 4.97 to 1.06; P ¼
.98 for superiority with a margin of 2 mm Hg). There were no signiﬁcant
safety differences between the two groups.
Comment: These ﬁndings contradict previously published clinical
data regarding renal denervation which showed large reductions in blood
pressure 6 months after denervation, and in the unblinded SIMPLICITY
HTN-2 Trial. Clearly it is important to conduct blinded trials with sham
controls in the evaluation of new medical devices before clinical adoption
of these devices occurs. Prior unblinded randomized trials may represent a
placebo effect as a treatment effect. Indeed, a placebo effect was demon-
strated in this trial with the sham procedure. While there was no direct mea-
surement to conﬁrm renal nerves were in fact de-enervated by the
SIMPLICITY catheter system, at this point it does not appear that there
is sufﬁcient evidence to promote wide spread adoption of renal denervation
in the treatment of resistant hypertension.
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Conclusions: A combination of D-dimer testing and clinical probabil-
ity assessment can improve the efﬁciency of diagnosis of upper extremity
DVT.
Summary: There are diagnostic algorithms combining clinical proba-
bility assessment, D-dimer testing, and ultrasonography that are widely
advocated for suspected DVT of the leg (Gibson NS et al, J Thromb Hae-
most 2009;7:2035-41). In patients with suspected UEDVT, D-dimer has
been evaluated as contributing to the diagnosis in only one series of 52
consecutive patients (Merminod T et al, Blood Coagul Fibrinolysis
2006;17:225-6). Clinical probability has been evaluated in patients with
UEDVT and the conﬁrmed incidence of UEDVT has been about 12%,
20%, and 70% in patients with low, intermediate and high clinical probability
of UEDVT (Constans J et al, Thromb Haemost 2008:99:202-7). However,
a combination of D-dimer testing and clinical probability has not been eval-
uated in patients with possible UEDVT and such an algorithm, if effective,
would be useful in that the large majority of patients evaluated for UEDVT
with ultrasonography alone, do not have the condition. The purpose of this
study was to test the safety and feasibility of a diagnostic algorithm in pa-
tients with clinically suspected UEDVT. The study took place in 16 hospi-
tals in Europe and the United States and consisted of 406 inpatients and
outpatients with suspected UEDVT. The diagnostic algorithm consisted
of sequential applications of a clinical decision score, Constans clinical deci-
sion score, that incorporated presence of localized pain, unilateral edema,
and the possibility of any other diagnosis, as well as D-dimer testing and ul-
trasonography. Patients were classiﬁed as likely or unlikely to have UEDVT.
In those with an unlikely score and normal D-dimer levels UEDVT was
considered excluded. All other patients had (repeated) compression ultraso-
nography to evaluate for UEDVT. The primary outcome was the 3-month
incidence of symptomatic UEDVT and pulmonary embolism in patients
with a normal diagnostic work-up. In 390 of the 406 patients (96%) the al-
gorithm was feasible and completed. In 87 patients (21%), an unlikely score
combined with normal D-dimer levels to exclude UEDVT. Superﬁcial
venous thrombosis and UEDVT were diagnosed in 54 (13%) and 103
(25%) patients, respectively. There were 249 patients with a normal diag-
nostic work-up including those with protocol violations who were then fol-
lowed for 3 months. One patient developed UEDVT during follow-up, for
an overall failure rate of the diagnostic algorithm of 0.4% (95% CI, 0.0%-
2.2%).
Comment: Although the study was not powered to show the safety of
various sub-strategies to exclude UEDVT, such as the Constans score alone
or D-dimer levels alone; if conﬁrmed by other studies, the algorithm pre-
sented would appear to have the potential to improve the efﬁciency of diag-
nosis of upper extremity DVT by eliminating the use of a large number of
ultrasound studies ultimately proving to be negative.
